| 李伊培 郗永义 张连成 高丽华 邵勇 刘羽 潘芸 高招刚 胡显文 陈惠鹏 张嵘.抗VEGF/VEGFR 靶向肿瘤血管药物的研究进展[J].,2014,14(16):3158-3162 |
| 抗VEGF/VEGFR 靶向肿瘤血管药物的研究进展 |
| Progress in Anti-tumor Angiogenesis Drugs Targeting VEGF/VEGFR |
| |
| DOI： |
| 中文关键词: VEGF/VEGFR 肿瘤血管生成 抗肿瘤药物 Aflibercept |
| 英文关键词: VEGF/VEGFR Tumor-associated angiogenesis Anti-tumor drugs Aflibercept |
| 基金项目:国家自然科学基金项目（30973670；81202445） |
|
| 摘要点击次数: 677 |
| 全文下载次数: 2576 |
| 中文摘要: |
| 研究表明，肿瘤的生长转移和新血管的生成有密切关系，其中血管内皮细胞生长因子（vascular endothelial growth factor，
VEGF）及其信号途径在肿瘤血管生成中起关键作用。阻断该途径的任何环节均可有效抑制肿瘤血管的生成，进而抑制肿瘤的生
长和转移。近年来，已有多种以VEGF/VEGFR 为靶点的抗肿瘤血管生成药物投入临床应用，其中bevacizumab 为第一个获批上市
的抗肿瘤血管生成药物。继bevacizumab 后，一种以基因工程手段获得的人Fc 融合蛋白Zaltrap 也成功在美国上市，这种杂交分
子的药代动力学明显优于单克隆抗体，能更好的遏制肿瘤血管的发生并消退已形成的肿瘤血管。在肿瘤的临床治疗中，Zaltrap 比
bevacizumab 显示出更大的优势。此外，VEGFC/D Trap 及小分子酪氨酸激酶抑制剂也能有效抑制肿瘤血管的生成。在此对以
VEGF/VEGFR 为靶点的抗肿瘤血管生成药物进行综述。 |
| 英文摘要: |
| Tumor growth and metastasis depend on angiogenesis, vascular endothelial growth factor（VEGF）and its signaling
pathway play a key role in tumor-associated angiogenesis. Blocking any step in this pathway can effectively inhibit the tumor-associated
angiogenesis and thereby inhibit the growth and metastasis of tumor. In recent years, there have been many anti-tumor angiogenesis drugs
that target VEGF/VEGFR in clinical application, in which bevacizumab was the first one approved. After bevacizumab, Zaltrap, a human
Fc fusion protein which was structured by genetic engineering, was also successful on sale in America. Pharmacokinetics of the fusion
protein is significantly better than that of the monoclonal antibodies. In the therapeutics to tumor, Zaltrap shows greater advantage than
bevacizumab. In addition, VEGFC/D Trap and tyrosine kinase inhibitors can also effectively inhibit tumor-associated angiogenesis. This
review aimed to summarize the anti-tumor angiogenesis drugs which target VEGF/VEGFR. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
